Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of AlphaNine Versus BeneFIX in Patients With Severe Hereditary Haemophilia B

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Key Inclusion Criteria:~* Participated in the previous study Efficacy and safety of factor IX (FIX) contained in Alphananine in patients with severe hereditary haemophilia B:~* Congenital deficiency in Factor IX (FIX)~* FIX residual activity of ≤2% of normal~* Had required FIX-containing products in the past and in clinical records that were collected data to assess a reliable estimation of at least 150 treatment exposure days to previous products~* Was able to receive treatment for more than 10 days for a 6-month period~Key Exclusion Criteria:~* Received a dose of FIX in the 7 days prior to the infusion~* FIX inhibitor level of \>0.5 Bethesda units (BU) or clinically relevant presence in the past (≥5 BU)~* Active bleeding at the moment of infusion~* Had a known allergic reaction to any BeneFIX component~* Exhibited symptoms of any intercurrent infection (ie, fever, chills, nausea) at the time of the first infusion~* Had any disease that might affect the distribution or metabolism of FIX and which could affect interpretation of the study (such as non-controlled diabetes mellitus)~* Had non-controlled arterial hypertension~* Had abnormal renal function (creatinine \>1.5 mg/dL)~* Had documented liver cirrhosis or any hepatic disorder with alanine aminotransferase (ALT) levels 2.5x upper limit of normal (ULN )~* Prevision to be concomitantly treated with other FIX-containing products~* Had conditions that might affect subject compliance (survival-limiting \[in 2 year time\] diseases, alcohol or other drug abuse, etc.)~* Unable to provide a storage plasma sample before the first dose of BeneFIX

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- BeneFIX (Type: EXPERIMENTAL): BeneFIX is a recombinant FIX provided in a vial containing 100 IU/mL lyophilized nonacog alfa accompanied with solvent for reconstitution and injection.

Based on this trial design, predict the completion outcome and termination type (if applicable).